Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) General Counsel Sells $134,460.00 in Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) General Counsel Iqbal Hussain sold 6,000 shares of the stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $22.41, for a total value of $134,460.00. Following the sale, the general counsel directly owned 105,386 shares in the company, valued at $2,361,700.26. This represents a 5.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Centessa Pharmaceuticals Stock Up 0.7%

Shares of CNTA opened at $23.02 on Friday. The company has a market capitalization of $3.08 billion, a price-to-earnings ratio of -12.86 and a beta of 1.57. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $9.60 and a 52 week high of $24.57. The stock’s 50-day moving average price is $20.34 and its 200-day moving average price is $15.86. The company has a quick ratio of 10.12, a current ratio of 10.11 and a debt-to-equity ratio of 0.32.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). On average, sell-side analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on CNTA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, October 8th. Lifesci Capital raised shares of Centessa Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, September 3rd. Wall Street Zen lowered Centessa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday. Guggenheim reaffirmed a “buy” rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Finally, Wells Fargo & Company started coverage on Centessa Pharmaceuticals in a report on Wednesday, September 3rd. They issued an “overweight” rating and a $31.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $32.38.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd increased its stake in Centessa Pharmaceuticals by 15,209.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock worth $46,000 after buying an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. purchased a new stake in shares of Centessa Pharmaceuticals during the first quarter worth approximately $47,000. Bank of New York Mellon Corp purchased a new stake in shares of Centessa Pharmaceuticals during the first quarter worth approximately $147,000. Fox Run Management L.L.C. acquired a new position in Centessa Pharmaceuticals in the 1st quarter valued at $160,000. Finally, Vestal Point Capital LP purchased a new position in Centessa Pharmaceuticals in the 1st quarter valued at $214,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.